“Imagine if vaccines didn’t have to be formulated as liquids. Imagine if they were cheap, safe, fast and agile to transport with no cold chain necessary, and nothing holding them back. Imagine the suffering that could be prevented, the costs that could be avoided and the communities and societies that could be set free. That, ultimately, is what Ziccum technology can deliver.” – Göran Conradson, CEO, ZICCUM

Ziccum is developing new dry-powder versions of the world’s most effective vaccines from bulk containers to convenient forms for administrations. These new, gently air-dried powder vaccines can be transported easily and cost-effectively, with no costly cold storage or refrigeration required.

With the company's patented technology LaminarPace, dry formulations of products that are currently available in liquid, or freeze-dried form are developed. This allows Ziccum to open up new markets, create new patents and generate revenue from the sale of licenses to the new form of preparation.

Through its patented technology LaminarPace, Ziccum is the only company in the world to offer gentle drying of vaccines at room temperature. This opens up the opportunity to develop and patent new processes of vaccines and offer better stability, longer durability and simpler storage and transportation requirements. This gives a competitive advantage, cost savings and the opportunity to address more and bigger markets. New forms of preparation and the process of producing these can also be protected by new patents so that the competitive advantage lasts over time. LaminarPace has been validated through internal, published studies and external projects where Ziccum has carried out feasibility studies on behalf of the client.

The company intends to license out rights to its IP portfolio, but also look at the value creation chain as a whole and investigate different options and possibilities to move up and take a larger portion of the value created. Through International partnerships and larger contracts spanning over several stake holders within the industry.

Ziccum, located in Lund, was founded as a spinout from Inhalation Sciences, which was successfully listed on Spotlight in September 2017. Ziccum followed the same path and was listed on Spotlight in October 25th, 2018.

For additional information about Ziccum please visit the company website: https://ziccum.com/

 

Business Oriented CFO

“Set vaccines free”

Vision
Ziccums vision is to provide safe and effective medicines in all environments and situations worldwide and to minimize expensive and impractical fridge and freezer transport and storage.

Possibilities
Do you have a desire to be a leading part of an innovative entrepreneur company working with products that both creates attention but also contribute to developing new dry-powder versions of the world’s most urgently needed vaccines? These new, gently air-dried formulations can be transported easily and cost-effectively, with no costly cold storage or refrigeration required. Ziccum has the technology to make a significant difference for large populations who need access to vaccines and drugs, and for large pharmaceutical companies that want to streamline the logistics of their products and thereby increase market potential.
With Ziccum’s unique and patented technology, LaminarPace® objective is to develop new formulations of vaccines. By developing dry formulations of products presently present only in liquid, or in freeze-dried form, Ziccum can open new markets and create new patents. Dry form is always sought in the development of new drugs. The benefits of dry form (tablets, powders, etc.) are many. It increases the stability of the product and thus its life span, it facilitates the entire transport chain from factory to patient, enabling the distribution of drugs to new locations where, for example, refrigerator and freezer storage is a major challenge. The company focus on a market (biologics) where the history, trends and needs clearly indicates the value of being able to produce products in dry form but where the technical solutions for doing this has been lacking.

Currently Ziccum is focusing on the next step – to adapt the technology for commercial production and present our offer to potential partners in the pharmaceutical industry. If you decide to work for Ziccum it means you will:
• work in a company that will have a paramount impact on possibilities to a paradigm shift concerning the ability to formulate dry formulations of vaccines
• work in a company with a clear objective - to develop and to grow Ziccum to a world leader in providing safe and effective vaccines in the area of dry formulation
• be a part of a company that will enable patients’ worldwide access to safer and more efficient vaccines
• work in a company with short decision paths and with a high level of personal responsibility
• close and frequent interactions with the CEO
• as the company is small, you must have a “can do” attitude and be comfortable in situations where you must be more “hands-on”

The market for biological drugs is large and in strong growth. In 2017, biological drugs accounted for one third of total drug sales globally, equivalent to $ 208 billion. By 2024, this figure is estimated to have increased to $ 380 billion or 38% of global pharmaceutical sales. [EvaluatePharma® World Preview 2018, Outlook to 2024, 11th Edition - June 2018]. The market for vaccines is $ 45 billion and is expected to significantly grow with 7%/year and an additional strong growth with new vaccines for Covid-19. Today about 5 billion vaccine doses are manufactured every year and an additional 3-5 billion covid-19 doses are expected to be produced.

The position
Ziccum is looking for an experienced and business driven CFO with leadership skills. The role will be responsible to ensure diligence and structure for financial management and reporting including being one of the professional guardians of shareholder value. As a fast growing, entrepreneurial company we need a CFO who can handle a multitude of strategic as well as tactical issues. The person needs to combine a solid financial understanding with a strong ability to execute with passion and integrity. Earlier experience from listed companies is an advantage as well as experience from small development companies in a global market. We also value a network and professional relations within leading financial institutions. The team currently consist of 5 people with different specialties and competencies, as well as several high professional international consultants connected to the company. Ziccum is planning to grow substantially the coming quarters recruiting to several positions.

Profile
We are looking for a driven and commercially minded CFO with leadership skills with previous project management experience of cross functional international collaborations. Plus a strong understanding of the specific environment and demands on a listed company. You are analytical and structured, informal yet diligent and understand the purpose of the numbers rather than just the numbers themselves. You are pragmatic and fast with a hands-on approach. It is also important to have proven leadership skills, and to be ambitious with a personal drive to take responsibility and work independently.

Contact information / Application
For inquires and more information about the position, please contact Jarl Molin, senior recruitment consultants at PeakSearch. Mail: jarl.molin@peaksearch.se phone: +46 70 560 20 56

Apply for the position at PeakSearch homepage http://www.peaksearch.se or send your CV directly to Jarl, see above.